E Fund Management Co. Ltd. Has $561,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

E Fund Management Co. Ltd. lessened its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 3.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,994 shares of the biopharmaceutical company’s stock after selling 13,777 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Fate Therapeutics were worth $561,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of FATE. Privium Fund Management B.V. bought a new position in shares of Fate Therapeutics during the 3rd quarter worth approximately $175,000. Thrivent Financial for Lutherans lifted its position in shares of Fate Therapeutics by 24.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 125,370 shares of the biopharmaceutical company’s stock worth $439,000 after buying an additional 24,804 shares during the period. Intech Investment Management LLC bought a new position in shares of Fate Therapeutics during the 3rd quarter worth approximately $108,000. FMR LLC lifted its position in shares of Fate Therapeutics by 25.9% during the 3rd quarter. FMR LLC now owns 227,981 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 46,892 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in shares of Fate Therapeutics by 1,307.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 174,148 shares of the biopharmaceutical company’s stock worth $610,000 after buying an additional 161,776 shares during the period. Institutional investors and hedge funds own 97.54% of the company’s stock.

Fate Therapeutics Stock Down 2.9 %

FATE stock opened at $1.01 on Friday. The company has a market cap of $115.03 million, a P/E ratio of -0.61 and a beta of 2.02. Fate Therapeutics, Inc. has a twelve month low of $0.88 and a twelve month high of $8.74. The business has a fifty day moving average of $1.38 and a 200-day moving average of $2.39.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.13. The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $1.57 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. As a group, equities research analysts anticipate that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

Insider Transactions at Fate Therapeutics

In other news, Director Redmile Group, Llc bought 397,964 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the completion of the transaction, the director now directly owns 12,884,277 shares in the company, valued at $21,645,585.36. The trade was a 3.19 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 5.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

FATE has been the subject of several analyst reports. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a research report on Thursday. Wells Fargo & Company cut their target price on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday. StockNews.com upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday. Finally, Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.50.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.